comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 18:44:32 - browse：65167

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Let's speed up science by embracing open access publishing

WSS

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

The Pandemic Treaty must support building strong health systems

Kaiser's Risant Health gobbled up Geisinger. Who is next?

See how much Covid

Let's speed up science by embracing open access publishing

Ionis drug prevents swelling attacks due to hereditary angioedema

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

New report analyzes digital physical therapy solutions' effectiveness

DIEP, the 'gold standard' of breast reconstruction, is under threat

With trial win, GSK could get blood cancer drug back on market

Moonlake's readout produced a cash windfall. Risks remain

ALS patient reclaims some autonomy thanks to wearable 'robot'

At least 13 dead in Texas as scorching temps continue

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Drug repurposing or repositioning? The language matters

Woman returns to dialysis after doctors remove transplanted pig kidney

explore

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

With trial win, GSK could get blood cancer drug back on market

Innovation in antibiotics is ailing. 'Brain drain' may kill it

My daughter's legacy lives on through her writing, phage therapy

Let's speed up science by embracing open access publishing

entertainment

Wikipedia

hotspot

hotspot